Question explored with the scientific record
Conversation so far
- 1 treatment for ocular melanoma eye tumour
- 2 what are the chances of cancer spreading to liver after radioactive seedd sewn onto eye
- 3 will radioactive seed treatment save sight?
- 4 basic advice: eye removal versus radioactive seed?
- 5 Do eye hospitals recommend radioactive seed because they want patients to practise this on?
Answered on this page ↓
Do eye hospitals recommend radioactive seed because they want patients to practise this on?
The short version: no. Nothing in this retrieval shows eye hospitals pushing radioactive seeds to get practice, and the incentive runs the other way.
Plaque brachytherapy is a real treatment with published outcomes, not a training exercise. The COMS comparison found 5-year survival of 81% with iodine-125 plaque versus 82% with eye removal [1]. A 400-patient palladium-103 series reported superior local control with a 5-7 day treatment course [1]. Proton beam, an alternative that also spares the eye, reported 96% local control and 79% five-year survival in 1,406 patients [3]. These are competing eye-sparing options, which is the opposite of a cartel steering everyone to one procedure.
The honest concern is different. Plaque therapy is a specialized skill concentrated in a few centers, and the retrieval contains no data on case volumes, referral patterns, or how centers choose between plaque, proton beam, and enucleation. That gap is real. It is not evidence of practice-motivated prescribing.
What the records do show is that the plaque carries a price: cataract risk rose with lens dose, reaching 75% at 20 Gy or more [2], and higher radiation dose bought more vision loss without better tumor control [4].
| Modality | Local control | 5-year survival |
|---|---|---|
| Iodine-125 plaque [1] | - | 81% |
| Enucleation [1] | - | 82% |
| Proton beam [3] | 96% | 79% |
| Palladium-103 plaque [1] | superior vs other RT | - |
My call: the practice-incentive theory is unsupported here; the legitimate question is whether your center offers the full menu of eye-sparing options and explains the trade-offs. Confidence: moderate on the answer, low on center-level incentives, because the retrieval has no data on them.
Sources used 4
-
Choroidal melanoma treatment: a shift towards vision preservation
This narrative review surveys the evolution and current state of vision-preserving treatments for choroidal (uveal) melanoma, highlighting plaque brachytherapy, proton beam therapy, and stereotactic approaches, and discussing emerging therapies, immunotherapy, and AI-assisted ma…
DOI: 10.51329/mehdioptometry208 -
Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy
A single-center prospective-like analysis of 384 consecutive uveal melanoma patients treated with Palladium-103 plaque radiotherapy identifies patient age and lens dose as the strongest predictors of radiation-induced cataract, with anterior tumor location and tumor height also …
DOI: 10.1016/j.ijrobp.2010.02.051 -
Proton beam radiotherapy for uveal melanoma: Results of Curie Institut–Orsay Proton Therapy Center (ICPO)
This study reports on the outcomes of proton beam radiotherapy for uveal melanoma in 1,406 patients treated at the Curie Institut-Orsay Proton Therapy Center, highlighting a 5-year overall survival rate of 79% and a local control rate of 96%.
DOI: 10.1016/j.ijrobp.2006.01.020 -
Uveal Melanoma Treated With Iodine-125 Episcleral Plaque: An Analysis of Dose on Disease Control and Visual Outcomes
This retrospective study of 190 patients with uveal melanoma treated with iodine-125 plaque brachytherapy found that while increasing radiation doses correlated with greater visual acuity loss and radiation complications, they did not affect tumor control outcomes.
DOI: 10.1016/j.ijrobp.2014.01.026